Mach7 Technologies (M7T) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
10 Jul, 2026Strategic reset and financial transformation
Achieved positive operating cash flow in Q2 and Q3, maintaining zero debt and a strong balance sheet with A$18.5M cash.
Cost base reduced by 6% through disciplined management and operational overhaul.
Recurring revenue represents 85% of total revenue, reflecting a shift from lumpy capital deals to a predictable model.
Leadership team revitalized, emphasizing cost discipline, commercial execution, and refreshed performance team.
Growth now prioritized following a reset year focused on internal restructuring.
Vision, strategy, and outlook
Aims to become the global imaging EMR by integrating patient images into electronic medical records and enhancing clinical workflows.
Transitioning from archive to modular architecture, positioning imaging as a core patient record layer.
Focus areas for FY27 include pipeline growth, sales momentum, improved delivery execution, partner leverage, leadership readiness, and cost efficiency.
CTO appointment and refreshed performance team align with strategy and innovation goals.
Fund growth from operating strength, maintaining cost discipline and staff engagement.
Market opportunity and industry trends
Enterprise imaging market projected to double by 2030, reaching AUD 4 billion.
Medical staff shortages and rising imaging volumes are accelerating adoption of AI and automation.
Open APIs, EMR interoperability, and hybrid cloud/on-prem solutions are key industry trends.
Security and compliance are critical, with healthcare organizations facing heightened cyber threats.
Modular solutions allow customers to modernize without high-risk system replacements.
Latest events from Mach7 Technologies
- Q4 FY26 saw positive cash flow, ARR growth, and key product and partnership milestones.M7T
Q4 2026 - Q3 FY26 saw positive cash flow, ARR growth, and a strong cash position amid cost discipline.M7T
Q3 2026 - Revenue fell 23% year-over-year, but recurring revenue and cost discipline support future growth.M7T
H1 2026 - Stable ARR, positive cash flow, and new product traction support a confident outlook.M7T
Q2 2026 - 16% revenue growth, recurring revenue covers 80% of OPEX, and cash flow is positive.M7T
H2 2025 - Record recurring revenue and sales orders drive positive cash flow and strong FY25 outlook.M7T
H2 2024 - Sales orders up 52%, recurring revenue and cash at record highs, subscription growth strong.M7T
Q4 2024 TU - Revenue up 33%, recurring revenue covers 80% of OpEx, and positive EBITDA with share buy-back announced.M7T
H1 2025 - Recurring revenue and cash flow surged, with FY25 growth guidance and buyback reaffirmed.M7T
Q2 2025 TU